PORTLAND, Ore., Dec. 11, 2017 (GLOBE NEWSWIRE) - Cromos™ Pharma, a premier regional contract research organization announced today that Stephanie Finnegan has been appointed as its Chief Operating Officer. Ms. Finnegan will join the company's US office and will oversee its European and US operations.
"We are very excited to see Ms. Finnegan joining our team," said Dr. Vlad Bogin, Cromos™ Pharma's CEO. "She brings decades of clinical research and business development experience and her addition marks a quantitative change in the company’s development. We plan to utilize Stephanie’s knowledge of US and international clinical operations to further Cromos™ Pharma's reputation of a fully integrated CRO capable of providing a full spectrum of services to biotech and pharma companies of all sizes," continued Dr. Bogin.
“Joining Cromos™ Pharma was an easy decision for me,” Ms. Finnegan said. “I was looking for an opportunity to do what I enjoy most; to work with a young and growing company looking to establish a global presence. After meeting with Dr. Bogin and the leadership team at Cromos, I knew that this was the right fit. The team is talented, eager, and dedicated to unimpeachable quality and client service. There is limitless potential here and I am honored to become a member of the Cromos family.”
Ms. Finnegan has nearly three decades of experience in the biopharmaceutical industry. Prior to joining Cromos™ Pharma, she was the president of a US-based CRO that operated predominantly in Eastern Europe, and helped to lead that CRO into the global market and establish a dominant position in biologics and biosimilars. Prior to joining the CRO, Ms. Finnegan founded and led the biopharmaceutical industry’s first contract manufacturer dedicated to the clinical development of biotherapeutics. Over the past twenty-five years, she has become a recognized thought leader in global clinical development strategy and execution.
About Cromos™ Pharma
Cromos™ Pharma, LLC is a US-based contract research organization (CRO) with strong operational presence in the post-Soviet space and in Eastern/Central Europe. The company provides a full spectrum of trial-related services which include clinical monitoring, regulatory approvals, medical writing, feasibility assessments, project management and warehousing. Cromos™ Pharma, LLC is a privately owned company.
Cromos Pharma is pleased to share news about our latest project - an international double-blind placebo-controlled clinical trial of RPH-104 in acute ST-Elevation Myocardial Infarction (STEMI). The trial involving patients in the US and in Russia will investigate how a biologic RPH-104 developed by R-Pharm can reduce an acute inflammatory response after myocardial infarction and lead to improved outcomes for STEMI patients.
Throughout March we have been highlighting colorectal cancer, the amazing teams of researchers who are continuously fighting this disease, as well as the millions of patients and families who have been deeply affected by this silent killer. To close out this month of awareness-raising we want to introduce you to a real-life hero and colon cancer survivor - Arlene.
March is Colorectal Cancer Awareness Month. Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide according to 2020 figures from the Global Cancer Observatory.
Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.
Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.